Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …

The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …

Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

Introduction Cytotoxic agents have immunomodulatory effects, providing a rationale for
combining atezolizumab (anti-programmed death-ligand 1 [anti–PD-L1]) with chemotherapy …

PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …

Background In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression …

Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of
cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients …

Abstract Introduction In the phase 3 CheckMate 9LA study, nivolumab plus ipilimumab with
chemotherapy prolonged overall survival (OS) versus chemotherapy alone. We report …

Background BRAF mutations occurring in 1%–5% of patients with non-small-cell lung
cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact …